Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent chronic liver disease that can progress to end-stage conditions with life-threatening complications, but no pharmacologic therapy has been approved
According to a recent paper authored by Professor Davids and published in the South African Medical Journal , IV glutathione treatments have so far only been deemed safe when administered for a few weeks at the most, with further studies needed to determine the safety of long-term use
1 This aligns with the MHRAs general public guidance, which advises that GLP-1 medicines including Wegovy shouldnt be taken during breastfeeding due to a lack of human safety data
Symptoms of alcoholic liver disease may vary between individuals
Had people been warned about the severity of these rare complications, they might not have taken Ozempic in the first place
This treatment not only supports weight loss but also improves blood sugar control, particularly for individuals with type 2 diabetes
